Comparison 2. Bile acids for chronic hepatitis B.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Risk of abnormal serum ALT at the end of treatment	1	112	Risk Ratio (M‐H, Fixed, 95% CI)	0.65 [0.45, 0.94]
1.1 UDCA versus no intervention	1	112	Risk Ratio (M‐H, Fixed, 95% CI)	0.65 [0.45, 0.94]
2 Serum ALT (IU/L) at the end of treatment	1	112	Mean Difference (IV, Fixed, 95% CI)	‐14.94 [‐21.20, ‐8.68]
2.1 UDCA versus no intervention	1	112	Mean Difference (IV, Fixed, 95% CI)	‐14.94 [‐21.20, ‐8.68]